Abstract

Philadelphia chromosome-positive acute myeloid leukemia (Ph +-AML) has a poor response to anthracycline- and cytarabine- containing regimens, high relapse rate, and dismal prognosis. Although therapy with imatinib and allogeneic stem cell transplantation (allo-SCT) is promising, relatively short follow-up limits understanding of long-term results of these therapies. This report describes the outcomes of 3 cases of Ph+-AML diagnosed and transplanted at the University of Nebraska Medical Center between 2004 and 2011. These patients, young and without major comorbidities, received induction therapy with 7 days of cytarabine and 3 days of idarubicin along with imatinib and consolidation therapy with high-dose cytarabine (with or without imatinib). All patients underwent 10/10 HLA-matched peripheral blood allo-SCT (sibling donor for first and third patients and unrelated donor for the second patient; all had acute graft-versus-host disease (GVHD), and the first and third patients had chronic GVHD. All patients are currently alive and experiencing complete remission at 116, 113, and 28 months after diagnosis, respectively. This report shows that the use of allo-SCT with resultant graft-versus-leukemia effect and the addition of imatinib can result in long-term remission and possible cure in some patients with Ph+-AML.

Original languageEnglish (US)
Pages (from-to)963-968
Number of pages6
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume12
Issue number7
DOIs
StatePublished - Jul 1 2014

Fingerprint

Philadelphia Chromosome
Stem Cell Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Acute Myeloid Leukemia
Cytarabine
Graft vs Host Disease
Idarubicin
Peripheral Blood Stem Cell Transplantation
Unrelated Donors
Anthracyclines
Therapeutics
Comorbidity
Siblings
Leukemia
Tissue Donors
Transplants
Recurrence
Imatinib Mesylate

ASJC Scopus subject areas

  • Oncology

Cite this

@article{d4326309daa0412bacb1a3485d870ad3,
title = "Allogeneic stem cell transplantation for philadelphia chromosome-positive acute myeloid leukemia",
abstract = "Philadelphia chromosome-positive acute myeloid leukemia (Ph +-AML) has a poor response to anthracycline- and cytarabine- containing regimens, high relapse rate, and dismal prognosis. Although therapy with imatinib and allogeneic stem cell transplantation (allo-SCT) is promising, relatively short follow-up limits understanding of long-term results of these therapies. This report describes the outcomes of 3 cases of Ph+-AML diagnosed and transplanted at the University of Nebraska Medical Center between 2004 and 2011. These patients, young and without major comorbidities, received induction therapy with 7 days of cytarabine and 3 days of idarubicin along with imatinib and consolidation therapy with high-dose cytarabine (with or without imatinib). All patients underwent 10/10 HLA-matched peripheral blood allo-SCT (sibling donor for first and third patients and unrelated donor for the second patient; all had acute graft-versus-host disease (GVHD), and the first and third patients had chronic GVHD. All patients are currently alive and experiencing complete remission at 116, 113, and 28 months after diagnosis, respectively. This report shows that the use of allo-SCT with resultant graft-versus-leukemia effect and the addition of imatinib can result in long-term remission and possible cure in some patients with Ph+-AML.",
author = "Bhatt, {Vijaya R} and Mojtaba Akhtari and Bociek, {Robert G} and Sanmann, {Jennifer N} and Ji Yuan and Dave, {Bhavana J} and Sanger, {Warren G.} and Anne Kessinger and Armitage, {James Olen}",
year = "2014",
month = "7",
day = "1",
doi = "10.6004/jnccn.2014.0092",
language = "English (US)",
volume = "12",
pages = "963--968",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "7",

}

TY - JOUR

T1 - Allogeneic stem cell transplantation for philadelphia chromosome-positive acute myeloid leukemia

AU - Bhatt, Vijaya R

AU - Akhtari, Mojtaba

AU - Bociek, Robert G

AU - Sanmann, Jennifer N

AU - Yuan, Ji

AU - Dave, Bhavana J

AU - Sanger, Warren G.

AU - Kessinger, Anne

AU - Armitage, James Olen

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Philadelphia chromosome-positive acute myeloid leukemia (Ph +-AML) has a poor response to anthracycline- and cytarabine- containing regimens, high relapse rate, and dismal prognosis. Although therapy with imatinib and allogeneic stem cell transplantation (allo-SCT) is promising, relatively short follow-up limits understanding of long-term results of these therapies. This report describes the outcomes of 3 cases of Ph+-AML diagnosed and transplanted at the University of Nebraska Medical Center between 2004 and 2011. These patients, young and without major comorbidities, received induction therapy with 7 days of cytarabine and 3 days of idarubicin along with imatinib and consolidation therapy with high-dose cytarabine (with or without imatinib). All patients underwent 10/10 HLA-matched peripheral blood allo-SCT (sibling donor for first and third patients and unrelated donor for the second patient; all had acute graft-versus-host disease (GVHD), and the first and third patients had chronic GVHD. All patients are currently alive and experiencing complete remission at 116, 113, and 28 months after diagnosis, respectively. This report shows that the use of allo-SCT with resultant graft-versus-leukemia effect and the addition of imatinib can result in long-term remission and possible cure in some patients with Ph+-AML.

AB - Philadelphia chromosome-positive acute myeloid leukemia (Ph +-AML) has a poor response to anthracycline- and cytarabine- containing regimens, high relapse rate, and dismal prognosis. Although therapy with imatinib and allogeneic stem cell transplantation (allo-SCT) is promising, relatively short follow-up limits understanding of long-term results of these therapies. This report describes the outcomes of 3 cases of Ph+-AML diagnosed and transplanted at the University of Nebraska Medical Center between 2004 and 2011. These patients, young and without major comorbidities, received induction therapy with 7 days of cytarabine and 3 days of idarubicin along with imatinib and consolidation therapy with high-dose cytarabine (with or without imatinib). All patients underwent 10/10 HLA-matched peripheral blood allo-SCT (sibling donor for first and third patients and unrelated donor for the second patient; all had acute graft-versus-host disease (GVHD), and the first and third patients had chronic GVHD. All patients are currently alive and experiencing complete remission at 116, 113, and 28 months after diagnosis, respectively. This report shows that the use of allo-SCT with resultant graft-versus-leukemia effect and the addition of imatinib can result in long-term remission and possible cure in some patients with Ph+-AML.

UR - http://www.scopus.com/inward/record.url?scp=84903979224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903979224&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2014.0092

DO - 10.6004/jnccn.2014.0092

M3 - Article

VL - 12

SP - 963

EP - 968

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 7

ER -